Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.49 |
| ▸ | KHK | P50053 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084323 | 0.92 | PLK1 (0.49) | PLK1KHKCHRNB2CHRNA4HTR7 | |
| SCHEMBL4101712 | 0.92 | PLK1 (0.49) | PLK1KHKCHRNB2CHRNA4HTR7 | |
| SCHEMBL4088456 | 0.92 | PLK1 (0.43) | PLK1KHKCHRNB2CHRNA4HTR7 | |
| SCHEMBL6503474 | 0.92 | PLK1 (0.43) | PLK1KHKCHRNB2CHRNA4HTR7 | |
| SCHEMBL4084182 | 0.92 | PLK1 (0.43) | PLK1KHKCHRNB2CHRNA4HTR7 | |
| SCHEMBL4088463 | 0.92 | PLK1 (0.43) | PLK1KHKCHRNB2CHRNA4HTR7 | |
| SCHEMBL4084191 | 0.92 | PLK1 (0.43) | PLK1KHKCHRNB2CHRNA4HTR7 | |
| SCHEMBL4084188 | 0.92 | PLK1 (0.43) | PLK1KHKCHRNB2CHRNA4HTR7 | |
| SCHEMBL4099674 | 0.91 | PLK1 (0.49) | PLK1KHK | |
| SCHEMBL4095424 | 0.91 | PLK1 (0.42) | PLK1KHKCHRNB2CHRNA4HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | claimed |
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | PLK1 1061/4885KHK 2675/4885CHRNB2 1720/4885 |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | PLK1 1156/4885KHK 2674/4885CHRNB2 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.